Introduction

This themed collection focuses on a central area of modern cancer research: how dysregulated signaling and altered protein networks can lead to malignancy, and how these dependencies might offer novel therapeutic opportunities.

The journal invites contributions on oncogenic signaling complexes, pathway crosstalk, and network rewiring. It also welcomes translational work on biomarkers, resistance mechanisms, and novel therapeutic strategies targeting such vulnerabilities.

Topics of interest include (but are not limited to):

Complexes and Networks:

• Signaling hubs, scaffold proteins, and regulatory complexes in cancer
• Dysregulated protein-protein interactions in oncogenic signaling
• Pathway crosstalk and network rewiring during tumor progression
• Structural and functional characterization of cancer-relevant interaction interfaces

Translation and Therapy:

• Biomarkers on network state, and therapeutic response
• Adaptive signaling responses and targeted therapy resistance
• Computational approaches to mapping signaling vulnerabilities
• Therapeutic targeting of protein interactions (e.g., degraders, small molecules, biologics)

Academic Editor

Dr. Dirk Geerts
Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands, and GenDx, Utrecht, The Netherlands.

Submission Guideline

Instructions for Authors: https://www.sciltp.com/journals/bmi/instructionForAuthors
Submission Link: https://sciflux.org/authors/submissions

Article Processing Charges (APCs) are waived before the submission deadline. All manuscripts will undergo peer review in accordance with the journal’s established policies and procedures. Final acceptance will be based on the peer-review reports and the evaluation of the Academic Editors and the Editor-in-Chief. Decisions will be made by the Editor-in-Chief or Academic Editors who have no conflicts of interest with any of the authors.